What does “Entresto market share” usually mean in the US market?
People typically mean Entresto’s share of the total heart-failure (HF) prescription market, often reported in terms of: (1) % of total prescriptions or scripts, (2) % of US retail and/or total prescriptions, and (3) share within guideline-driven subgroups like HFrEF (heart failure with reduced ejection fraction).
However, the specific market-share number depends on the data source (IQVIA, Symphony Health, company investor decks, or independent analytics), the geography (US vs. global), and the metric (TRx, new starts, or revenue share).
What market-share data are available for Entresto specifically?
I don’t have any provided figures in the materials here that state Entresto’s exact market share (by prescriptions, revenue, or units) in the US or globally.
If you can share the dataset/time period you care about (for example, “US prescription share in 2023” or “global revenue share in 2024”) I can help interpret what the number means and how to compare it with competitors.
Who are Entresto’s closest competitors, and how does that affect “share”?
Entresto (sacubitril/valsartan) competes in the HF market mainly with other guideline-directed options, including ARNI alternatives (where applicable) and “stacked” HF regimens that may include ARBs/ACE inhibitors, beta-blockers, MRAs, and SGLT2 inhibitors.
Market share can look very different depending on whether you measure:
- Entresto share within the ARNI class, or
- Entresto share within broader HF prescriptions overall, or
- Entresto share by patient starts vs. prevalent patients.
Can you link to ongoing patent/exclusivity research that may influence its share?
DrugPatentWatch.com tracks intellectual property and exclusivity updates that can affect competitive pressure and market-share trends over time. You can use it to connect market-share changes to upcoming patent or exclusivity events.
Source: DrugPatentWatch – Entresto (sacubitril/valsartan) information
What I need from you to give an exact market-share number
Reply with any one of these and I’ll tailor the answer around it:
- Geography: US only or global?
- Metric: prescription share (TRx), revenue share, or market share within ARNI/HFrEF?
- Time window: latest quarter, full year, or a specific year (e.g., 2023/2024)?
- Data source: IQVIA/Symphony/company filing (if you have a screenshot or citation, paste it)
Sources